Asep Medical Featured in National Documentary
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) is featured in a national documentary series called 'Empowered', hosted by Meg Ryan, airing on Public Television in the US. The series, reaching over 60 million households, highlights Asep's innovative AI-based sepsis diagnostic test. The company's technology, SepsetER, can predict sepsis onset in 9 out of 10 ICU patients and 7 out of 10 emergency department patients.
Developed by a team at the University of British Columbia, the test uses AI to identify genes involved in sepsis-related immune dysfunction. With sepsis responsible for one in five deaths worldwide, Asep's technology aims to address the critical need for early diagnosis, as every hour of delay increases the risk of death by 7.6%.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) è protagonista di una serie documentaria nazionale chiamata 'Empowered', condotta da Meg Ryan, trasmessa dalla Televisione Pubblica negli Stati Uniti. La serie, che raggiunge oltre 60 milioni di famiglie, mette in evidenza il test diagnostico per sepsi basato su AI di Asep. La tecnologia dell’azienda, SepsetER, è in grado di prevedere l'insorgenza della sepsi nel 90% dei pazienti in terapia intensiva e nel 70% dei pazienti nei reparti di emergenza.
Sviluppato da un team dell'Università della Columbia Britannica, il test utilizza l'AI per identificare i geni coinvolti nella disfunzione immunitaria correlata alla sepsi. Con la sepsi responsabile di una morte su cinque a livello mondiale, la tecnologia di Asep mira a rispondere all'urgente necessità di una diagnosi precoce, poiché ogni ora di ritardo aumenta il rischio di morte del 7,6%.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) aparece en una serie documental nacional titulada 'Empowered', presentada por Meg Ryan, que se emite en la Televisión Pública de EE. UU. La serie, que llega a más de 60 millones de hogares, destaca la innovadora prueba diagnóstica de sepsis basada en IA de Asep. La tecnología de la empresa, SepsetER, puede predecir la aparición de sepsis en 9 de cada 10 pacientes de UCI y 7 de cada 10 pacientes en las salas de emergencia.
Desarrollada por un equipo de la Universidad de Columbia Británica, la prueba utiliza IA para identificar los genes involucrados en la disfunción inmune relacionada con la sepsis. Con la sepsis siendo responsable de una de cada cinco muertes en el mundo, la tecnología de Asep busca abordar la necesidad crítica de diagnóstico temprano, ya que cada hora de retraso aumenta el riesgo de muerte en un 7,6%.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF)는 메그 라이언이 진행하는 'Empowered'라는 국립 다큐멘터리 시리즈에 출연하고 있으며, 미국 공영 방송에서 방영됩니다. 이 시리즈는 6천만 가구 이상에 도달하며, Asep의 혁신적인 AI 기반 패혈증 진단 테스트를 강조합니다. 회사의 기술인 SepsetER는 중환자실 환자 10명 중 9명과 응급실 환자 10명 중 7명에서 패혈증 발생을 예측할 수 있습니다.
브리티시컬럼비아대학교 팀에 의해 개발된 이 테스트는 AI를 사용하여 패혈증 관련 면역 기능 장애에 관여하는 유전자를 식별합니다. 패혈증이 전 세계적으로 사망자의 5명 중 1명의 원인인 만큼, Asep의 기술은 조기 진단의critical need에 대응하기 위해 고안되었으며, 지연될 경우 사망 위험이 7.6% 증가합니다.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) est présenté dans une série documentaire nationale intitulée 'Empowered', animée par Meg Ryan, diffusée sur la Télévision Publique aux États-Unis. La série, qui atteint plus de 60 millions de foyers, met en avant le test de diagnostic de sepsis innovant d'Asep basé sur l'IA. La technologie de l'entreprise, SepsetER, peut prédire l'apparition de la sepsis chez 9 patients sur 10 en unité de soins intensifs et 7 patients sur 10 aux urgences.
Développé par une équipe de l'Université de Colombie-Britannique, le test utilise l'IA pour identifier les gènes impliqués dans la dysfonction immunitaire liée à la sepsis. Avec la sepsis responsable d'un décès sur cinq dans le monde, la technologie d'Asep vise à répondre à la nécessité urgente d'un diagnostic précoce, car chaque heure de retard augmente le risque de décès de 7,6 %.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) ist Teil einer nationalen Dokumentarserie mit dem Titel 'Empowered', die von Meg Ryan moderiert wird und im öffentlich-rechtlichen Fernsehen der USA ausgestrahlt wird. Die Serie erreicht über 60 Millionen Haushalte und hebt den innovativen AI-basierten Sepsis-Diagnosetest von Asep hervor. Die Technologie des Unternehmens, SepsetER, kann den Ausbruch von Sepsis bei 9 von 10 Patienten auf der Intensivstation und 7 von 10 Patienten in der Notaufnahme vorhersagen.
Der Test wurde von einem Team der University of British Columbia entwickelt und nutzt KI, um Gene zu identifizieren, die an der sepsisbedingten Immunfunktionsstörung beteiligt sind. Da Sepsis für einen von fünf Todesfällen weltweit verantwortlich ist, zielt die Technologie von Asep darauf ab, dem dringenden Bedarf an einer frühen Diagnose gerecht zu werden, da jede Stunde Verzögerung das Sterberisiko um 7,6 % erhöht.
- Featured in a national documentary series reaching over 60 million US households, increasing visibility
- SepsetER test can predict sepsis onset in 90% of ICU patients and 70% of emergency department patients
- Innovative AI-based technology addresses a global health crisis responsible for 20% of deaths worldwide
- Potential for wide distribution to US hospitals once FDA cleared
- FDA clearance still pending for the sepsis diagnostic test
- Technology not yet commercially available or generating revenue
Asep was selected to be a part of a special series titled Empowered, Hosted by Meg Ryan, focusing on science, technology and medicine leaders.
In July of 2023, one of Asep's news releases announcing its groundbreaking AI-based technology for the rapid identification of sepsis caught the attention of the producers of the docuseries. Sepsis is a debilitating and severe disease that is responsible for one in five deaths worldwide1, and essentially all deaths from pandemic microbes like COVID-19. After a few meetings, the producers decided to bring the Asep story to its audience of over 60 million households in the US. The segment is distributed to over 170 Public Television stations in the US and will continue running for about a year.
"This is an exciting opportunity for us to help educate a large audience about the seriousness of sepsis and provide hope for a faster, more reliable diagnostic tool for emergency room teams worldwide," said Dr. Hancock. "Once our technology is FDA cleared, we expect to see our test kits widely distributed to hospitals across the US."
According to Dr. Evan Haney, Asep's CSO, "It is critical to identify sepsis as early as possible due to the
The technology was developed using an innovative team approach, including microbiologists and computer scientists at the University of
Chief Operating Officer Tim Murphy said, "We hope that current and prospective investors will take the time to tune in to PBS and learn a little more about our Company and the great work our scientific team is doing to tackle a global health crisis where every hour counts."
ABOUT ASEP MEDICAL HOLDINGS INC.
Asep Medical Holdings Inc. (asepmedical.com) is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine. The Company is a consolidation of three existing private companies, all with technology in advanced development — Sepset Biosciences Inc. (proprietary diagnostic tools to enable the early and timely identification of sepsis), ABT Innovations Inc. (broad-spectrum therapeutic agents to address multi-drug resistant biofilm infections), and SafeCoat Medical Inc. (an antimicrobial peptide, anti-fouling medical device coating technology).
Sepset Biosciences Inc. (sepset.ca) is developing a diagnostic technology that involves a patient gene expression signature that helps assess the development of severe sepsis, one of the significant diseases leading to antibiotic failure, since antibiotics are the primary treatment for sepsis. Sepsis was responsible for nearly
ABT Innovations Inc.'s (abtinnovations.ca) peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear-nose and throat, sinusitis, orthopaedic, etc.), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. The company is in the pre-clinical development phase with promising data.
SafeCoat Medical Inc.'s (safecoatmedical.com) technology incorporates self-assembling biocompatible polymers combined with conjugated antimicrobial peptides and applied to virtually any surface as stable antimicrobial and/or anti-fouling coatings. Of particular interest is the application of this versatile antimicrobial coating to various medical devices and implants that often become contaminated with biofilm infections. SafeCoat is optimizing methods to manufacture and apply these anti-bacterial coatings to a host of surfaces and can tailor the composition of the coating and associated peptide sequences for any desired application.
FORWARD-LOOKING STATEMENTS —
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to the successful clinical testing of our Sepsis in vitro diagnostic test and its intended filing for regulatory market authorization; the Company not receiving regulatory market authorization as planned or at all; the undertaking of pre-clinical studies on our lead therapeutic, with the expectation that this will lead to fast-track clinical trials; the timeframe for identification of sepsis with the company's products; the potential opportunities for the generation of revenue; the therapeutic benefits of the company's products; and other statements regarding the company's proposed business plans. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks including the risk that the company's products may not perform as expected; that the company may not receive the requisite regulatory market authorization or results of testing; the Company's testing of the products may not be successful and market authorization may not be obtained in the estimated timelines or at all; the company may not be able to generate revenue from its products as expected or at all; the market for the company's products may not be as described in this news release; and various other risk factors identified in the Asep Medical Inc.'s prospectus dated November 9, 2021, and in the company's management discussion and analysis, available for review under the Company's profile at www.sedar.com and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
ENDNOTES
1 https://www.biophysics.org/2024meeting#/
2 Kumar, A. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34, 1589–1596 (2006).
View original content to download multimedia:https://www.prnewswire.com/news-releases/asep-medical-featured-in-national-documentary-302212094.html
SOURCE ASEP Medical Holdings Inc.
FAQ
What is Asep Medical Holdings' stock symbol?
What is the name of Asep Medical's sepsis diagnostic test?
How accurate is Asep Medical's SepsetER test in predicting sepsis?
When will Asep Medical's documentary air on Public Television?
